Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients
Safety, Pharmacokinetics and Antiviral Effect of BI 201335 NA in HCV-1 Infected Patients Treated for 28 Days for Treatment naïve and Experienced Patients Treated in Combination With Peg Interferon Alfa-2a and Ribavirin
Sponsor: Boehringer Ingelheim
This PHASE2 trial investigates Hepatitis C and Pharmacokinetics and is currently completed. Boehringer Ingelheim leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jul 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .